Albert Beckers – Trademark Portfolio

Entity Type: 01

Albert Beckers holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include VIRGIL THERAPEUTICS.

Soiron-Centre 47

B-4861 Soiron

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Albert Beckers's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Albert Beckers have?

Albert Beckers has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Albert Beckers file in?

Albert Beckers files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What are Albert Beckers's most well-known trademarks?

Albert Beckers's registered trademark portfolio includes well-known marks such as VIRGIL THERAPEUTICS. These are among 1 currently registered trademark in the portfolio.

What is Albert Beckers's trademark registration success rate?

Albert Beckers has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.